

# Emily Figueiredo Vieira Neves Yuki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1821473/publications.pdf>

Version: 2024-02-01

19  
papers

426  
citations

840776  
11  
h-index

839539  
18  
g-index

21  
all docs

21  
docs citations

21  
times ranked

462  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. <i>Rheumatology</i> , 2022, 61, 3351-3361.   | 1.9  | 13        |
| 2  | Impact of Distinct Therapies on Antibody Response to <sc>SARSâ€CoV</sc>â€2 Vaccine in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2022, 74, 562-571.   | 3.4  | 25        |
| 3  | Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. <i>Lancet Rheumatology</i> , The, 2022, 4, e113-e124. | 3.9  | 24        |
| 4  | Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases. <i>Brain, Behavior, and Immunity</i> , 2022, 101, 49-56.  | 4.1  | 18        |
| 5  | Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 710-719.   | 0.9  | 16        |
| 6  | Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients. <i>Journal of Applied Physiology</i> , 2022, 132, 682-688.   | 2.5  | 2         |
| 7  | Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity. <i>Clinical Rheumatology</i> , 2022, 41, 2079-2089.  | 2.2  | 7         |
| 8  | Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1036-1043.  | 0.9  | 30        |
| 9  | Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study. <i>Lancet HIV</i> , the, 2022, 9, e323-e331.  | 4.7  | 36        |
| 10 | SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy. <i>Rheumatology</i> , 2022, 61, SI169-SI174.   | 1.9  | 9         |
| 11 | Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 889-897.   | 0.9  | 42        |
| 12 | Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment. <i>Journal of Clinical Rheumatology</i> , 2021, 27, 248-259.  | 0.9  | 18        |
| 13 | One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels. <i>Lupus</i> , 2021, 30, 956-964.  | 1.6  | 3         |
| 14 | Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. <i>Nature Medicine</i> , 2021, 27, 1744-1751.   | 30.7 | 148       |
| 15 | Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity. <i>Lupus</i> , 2021, 30, 1915-1922.   | 1.6  | 3         |
| 16 | Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0010002.   | 3.0  | 5         |
| 17 | Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis. <i>Lupus</i> , 2020, 29, 560-568.   | 1.6  | 18        |
| 18 | Ankylosing spondylitis and psoriatic arthritis: revisiting screening of latent tuberculosis infection and its follow-up during anti-tumor necrosis factor therapy in an endemic area. <i>Clinics</i> , 2020, 75, e1870.   | 1.5  | 4         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Longitudinal Extensive Transverse Myelitis and Central Diabetes Insipidus. Journal of Clinical Rheumatology, 2017, 23, 122-124. | 0.9 | 0         |